Quince Therapeutics to Participate at Investor Events in December 2025
Quince Therapeutics, Inc. (QNCX)
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior management will participate at three investor events in December 2025:Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, with a fireside chat beginning at 10:30 a.m. Eastern Time. Access to the company’s fireside chat will be accessible on the Events page of Quince’s Investor Relations website here. An archive of the webcast will be available shortly following the end of the live event.Charles Ryan, J.D., Ph.D., Quince’s President, will participate at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025. This event will include participation on a panel showcasing rare disease companies with key ne
Show less
Read more
Impact Snapshot
Event Time:
QNCX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNCX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNCX alerts
High impacting Quince Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
QNCX
News
- Quince Therapeutics (NASDAQ:QNCX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $4.00 price target on the stock.MarketBeat
- Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsBusiness Wire
- Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaBusiness Wire
- Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual MeetingBusiness Wire
QNCX
Earnings
- 11/12/25 - Miss
QNCX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 8-K
- 11/12/25 - Form 10-Q
- QNCX's page on the SEC website